Gastrointestinal Cancer News

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.

Young adult survivors of colorectal cancer exhibited low overall health-related quality of life scores, with longer-term survivors reporting worse social and functional well-being than those diagnosed more recently.

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.

The combination of panitumumab, ipilimumab and nivolumab induced responses among patients with metastatic colorectal cancer, according to phase 2 study results presented at Gastrointestinal Cancers Symposium.

The FDA approved fam-trastuzumab deruxtecan-nxki for treatment of certain patients with gastric or gastroesophageal adenocarcinoma.

A noninvasive multimodal blood test demonstrated high sensitivity and specificity for the detection of colorectal advanced neoplasia, according to prospective study results presented at Gastrointestinal Cancers Symposium.

The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients with gastric cancer and peritoneal metastases, according to study results presented at Gastrointestinal Cancers Symposium.

Edith P. Mitchell, MD, FACP, FCPP, FRCP, has been recognized as a fellow of the Royal College of Physicians of London.

The addition of vemurafenib to irinotecan and cetuximab improved PFS and response rates among patients with BRAF V600E-mutant metastatic colorectal cancer, according to study results published in Journal of Clinical Oncology.

Roswell Park Comprehensive Cancer Center announced the hiring or promotion of several people across clinical, administrative and research departments.